Neuraxis, INC
Close on Oct 19, 2026
- Market cap
- $95.14M
- P/E (TTM)
- –
- Dividend yield
- –
About Neuraxis
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Neuraxis, Inc. is a medical technology company that develops neuromodulation therapies for chronic and debilitating conditions of the gastrointestinal digestive system caused by disorders of gut-brain interaction. Its primary offering is IB-Stim, a proprietary Percutaneous Electrical Nerve Field Stimulation medical device cleared by the FDA to treat functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms in patients eight years of age and older. The company also offers the Rectal Expulsion Device, which evaluates rectal neuromuscular function and tests for rectal hypersensitivity in adults. Target customers include pediatric and adult patients treated by pediatricians, pediatric gastroenterologists, and trained healthcare providers in clinical settings.
The company operates in the United States and holds a Federal Supply Schedule contract with the federal government to supply its IB-Stim products. Neuraxis maintains its corporate headquarters and principal executive offices in Carmel, Indiana.
Summary of the business section of Neuraxis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Neuraxis, INC
- Founded
- 2011
- Headquarters
- Carmel, IN
- Address
- 11611 N. Meridian St, Suite 330 46032
- Phone
- (812) 689-0791
- Employees
- 24, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey
Stock & identifiers
- Ticker
- NRXS
- Exchange
- NYSE
- IPO date
- Aug 11, 2023
- Shares outstanding
- 13M, Aug 6, 2026
- Public float
- $20.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1933567
- CUSIP
- 64134X201
- ISIN
- US64134X2018
- EIN
- 45-5079684
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian Allen Carrico | Chief Executive Officer, Director | 227,336 |
| Craig Thomas Blanchard | Chief Commercial Officer | – |
| Adrian Miranda | CMO, SVP Science & Tech | 199,106 |
| Thomas Joeseph Carrico | CRO, CCO, CPO | 199,345 |
| Timothy Robert Henrichs | Chief Financial Officer | 7,593 |
| Gil Aharon | Director | 628,181 |
| Kristin A. Ferge | Director | 67,072 |
| Jane Elizabeth Keyser | Director | 72,408 |
| Bradley Mitchell Watkins | Director | 72,408 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brian Carrico | $936.44K | $1.32M | $651.73K | $72 | – |
| FY2024 Brian Carrico | $578.38K | $578.38K | $460.08K | $37 | – |
| FY2023 Brian Carrico | $839.40K | $839.40K | $367.08K | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 24 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 15, 2024 | Late filing | Notification of late filing |
| Apr 1, 2024 | Late filing | Notification of late filing |
| Nov 14, 2023 | Late filing | Notification of late filing |
| Aug 11, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 8, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |